Suppr超能文献

Ⅰ型干扰素在癌症免疫中的双重作用

Opposing Roles of Type I Interferons in Cancer Immunity.

机构信息

Princess Margaret Cancer Centre, University Health Network Toronto, Ontario M5G 2M9, Canada; email:

Department of Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

出版信息

Annu Rev Pathol. 2021 Jan 24;16:167-198. doi: 10.1146/annurev-pathol-031920-093932. Epub 2020 Dec 2.

Abstract

The immune system is tasked with identifying malignant cells to eliminate or prevent cancer spread. This involves a complex orchestration of many immune cell types that together recognize different aspects of tumor transformation and growth. In response, tumors have developed mechanisms to circumvent immune attack. Type I interferons (IFN-Is) are a class of proinflammatory cytokines produced in response to viruses and other environmental stressors. IFN-Is are also emerging as essential drivers of antitumor immunity, potently stimulating the ability of immune cells to eliminate tumor cells. However, a more complicated role for IFN-Is has arisen, as prolonged stimulation can promote feedback inhibitory mechanisms that contribute to immune exhaustion and other deleterious effects that directly or indirectly permit cancer cells to escape immune clearance. We review the fundamental and opposing functions of IFN-Is that modulate tumor growth and impact immune function and ultimately how these functions can be harnessed for the design of new cancer therapies.

摘要

免疫系统的任务是识别恶性细胞,以消除或防止癌症扩散。这涉及到许多免疫细胞类型的复杂协调,这些细胞共同识别肿瘤转化和生长的不同方面。作为回应,肿瘤已经发展出逃避免疫攻击的机制。I 型干扰素 (IFN-Is) 是一类在病毒和其他环境应激源的刺激下产生的促炎细胞因子。IFN-Is 也被认为是抗肿瘤免疫的重要驱动因素,强烈刺激免疫细胞消除肿瘤细胞的能力。然而,IFN-Is 发挥了更复杂的作用,因为长期刺激会促进反馈抑制机制,导致免疫衰竭和其他有害影响,这些影响直接或间接地使癌细胞逃避免疫清除。我们回顾了调节肿瘤生长和影响免疫功能的 IFN-Is 的基本和相反功能,以及这些功能如何被用于设计新的癌症治疗方法。

相似文献

1
Opposing Roles of Type I Interferons in Cancer Immunity.
Annu Rev Pathol. 2021 Jan 24;16:167-198. doi: 10.1146/annurev-pathol-031920-093932. Epub 2020 Dec 2.
2
Type I Interferon in Chronic Virus Infection and Cancer.
Trends Immunol. 2017 Aug;38(8):542-557. doi: 10.1016/j.it.2017.05.005. Epub 2017 May 31.
3
A Dual Role of Type I Interferons in Antitumor Immunity.
Adv Biosyst. 2020 Nov;4(11):e1900237. doi: 10.1002/adbi.201900237. Epub 2020 Mar 13.
4
Engineering interferons for cancer immunotherapy.
Biomed Pharmacother. 2024 Oct;179:117426. doi: 10.1016/j.biopha.2024.117426. Epub 2024 Sep 8.
5
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.
J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI143296.
6
Type I interferons in anticancer immunity.
Nat Rev Immunol. 2015 Jul;15(7):405-14. doi: 10.1038/nri3845. Epub 2015 Jun 1.
7
Immune responses to malignancies.
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83. doi: 10.1016/j.jaci.2009.09.045. Epub 2010 Jan 12.
8
Type I interferons and dendritic cells in cancer immunotherapy.
Int Rev Cell Mol Biol. 2019;348:217-262. doi: 10.1016/bs.ircmb.2019.06.001. Epub 2019 Jun 20.
9
Tumor-host immune interactions and dendritic cell dysfunction.
Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7.
10
IFN-I signaling in cancer: the connection with dysregulated Insulin/IGF axis.
Trends Endocrinol Metab. 2022 Aug;33(8):569-586. doi: 10.1016/j.tem.2022.04.009. Epub 2022 Jun 9.

引用本文的文献

2
Radiotherapy elicits immunogenic cell death and metabolic shifts in the tumor microenvironment: implications for immunotherapy.
Int J Med Sci. 2025 Jul 11;22(13):3277-3291. doi: 10.7150/ijms.109515. eCollection 2025.
3
Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.
MedComm (2020). 2025 Jul 15;6(8):e70274. doi: 10.1002/mco2.70274. eCollection 2025 Aug.
5
R-loops: a key driver of inflammatory responses in cancer.
Exp Mol Med. 2025 Jul 8. doi: 10.1038/s12276-025-01495-0.
6
Tumor microenvironments with an active type I IFN response are sensitive to inhibitors of heme degradation.
JCI Insight. 2025 Jul 8;10(16). doi: 10.1172/jci.insight.191017. eCollection 2025 Aug 22.
8
The prostacyclin receptor PTGIR is a NRF2-dependent regulator of CD8 T cell exhaustion.
Nat Immunol. 2025 Jul;26(7):1139-1151. doi: 10.1038/s41590-025-02185-9. Epub 2025 Jun 27.
9
Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities.
Antioxidants (Basel). 2025 Jun 15;14(6):735. doi: 10.3390/antiox14060735.

本文引用的文献

3
Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.
Mol Ther. 2020 Apr 8;28(4):1043-1055. doi: 10.1016/j.ymthe.2020.01.027. Epub 2020 Feb 4.
5
PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection.
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4292-4299. doi: 10.1073/pnas.1917298117. Epub 2020 Feb 7.
6
Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence.
Genes Dev. 2020 Mar 1;34(5-6):428-445. doi: 10.1101/gad.331272.119. Epub 2020 Jan 30.
7
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4 T Cells.
Immunity. 2020 Jan 14;52(1):151-166.e6. doi: 10.1016/j.immuni.2019.12.007. Epub 2020 Jan 7.
8
9
IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.
Mol Med Rep. 2020 Jan;21(1):445-453. doi: 10.3892/mmr.2019.10816. Epub 2019 Nov 12.
10
Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity.
Cell Rep. 2019 Oct 29;29(5):1236-1248.e7. doi: 10.1016/j.celrep.2019.09.065.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验